News >

Telaglenastat/Cabozantinib Combo Shows Early Activity in mRCC

Brandon Scalea
Published: Tuesday, Jun 25, 2019

Funda Meric-Bernstam, MD

Funda Meric-Bernstam, MD
Telaglenastat (CB-839) plus cabozantinib (Cabometyx) showed encouraging clinical activity and tolerability in heavily pretreated patients with metastatic renal cell carcinoma (mRCC), said Funda Meric-Bernstam, MD.

Meric-Bernstam F, Lee RJ, Carthon BC, et al. CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): results of a phase I study. J Clin Oncol. 2019;37(suppl 7; abstr 549). doi: 10.1200/JCO.2019.37.7_suppl.549.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication